Related Experiment Videos
Alternative technologies to generate monoclonal antibodies
T Stigbrand1, K R Ahlström, B Sundström
1Department of Medical Biochemistry and Biophysics, University of Umea, Sweden.
Acta Oncologica (Stockholm, Sweden)
|January 1, 1993
Summary
New technologies enhance hybridomas for monoclonal antibody production, improving diagnostic and therapeutic applications. Advances in antibody fragmentation and recombinant DNA techniques offer greater versatility.
Area of Science:
- Biotechnology
- Immunology
- Molecular Biology
Background:
- Hybridomas are crucial for producing monoclonal antibodies (mAbs).
- Existing technologies for mAb generation and modification have limitations.
- Diagnostic and therapeutic applications require advanced mAb formats.
Purpose of the Study:
- To review recent technological advancements in hybridoma technology for mAb production.
- To discuss novel methods for antibody fragmentation and engineering.
- To explore the future implications of these technologies in medicine.
Main Methods:
- Review of proteolytic procedures for antibody fragmentation (e.g., Fab2', Fab).
- Analysis of recombinant DNA techniques for engineering antibody fragments (e.g., chimeric, humanized, Fv, single-chain Fv).
- Synthesis of current research and future trends in hybridoma and mAb technology.
Main Results:
- Emerging technologies enable precise modification of hybridomas.
- Advanced antibody fragments (Fab2', Fab, Fv, scFv) can be generated efficiently.
- These advancements significantly enhance the potential for diagnostic and therapeutic uses of mAbs.
Conclusions:
- Recent technological innovations are making hybridomas more adaptable for clinical applications.
- Engineered antibody fragments offer improved specificity and efficacy.
- Further development promises expanded roles for mAbs in healthcare.